(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Recommendations

Info

Expression of p95 HER2 and response to trastuzumab in breast cancer HER2-positive MBC patients receiving trastuzumab (N=46) p185 HER2 (n=37) ORR: 51.4% p=0.029 p95 HER2 (n=9) ORR: 11.1% Scaltriti et al. J Natl Cancer Inst 2007;99:628–38
Trastuzumab Capecitabine von Minckwitz, JCO 2009 How to best treat patients beyond progression ? Progression after anthracycline/taxane/trastuzumab Lapatinib Capecitabine Randomized clinical trials Geyer, NEJM 2006 Trastuzumab Lapatinib Blackwell, SABCS 2009
Page 1 and 2: Utilizzo dei farmaci nei diversi co
Page 3 and 4: HER2 positive breast cancer “Targ
Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
Page 9 and 10: Antibody-Dependent Cellular Cytotox
Page 11 and 12: Potenziale meccanismo di trastuzuma
Page 13: Malattia adiuvante
Page 17 and 18: DFS: Sequential (Arm B: AC → T
Page 19 and 20: Malattia Neo- adiuvante
Page 21 and 22: Studio NOAH: Event Free Survival ne
Page 23 and 24: Trastuzumab has transformed the pro
Page 25 and 26: Definition of resistance In most tu
Page 27: Truncated HER2 (p95 HER2 ): clinica
Page 31 and 32: GBG 26/BIG 03-05: main results Cape
Page 33 and 34: Phase III, randomised, controlled s
Page 35 and 36: Lapatinib • Binds to intracellula
Page 37 and 38: Lapatinib may sensitise HER2 positi
Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
Page 41 and 42: HER2 dimerization is key to signali
Page 43 and 44: Trastuzumab binds to subdomain IV o
Page 45 and 46: Trastuzumab and pertuzumab may have
Page 47 and 48: Receptor-T-DM1 complex is internali

(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Create successful ePaper yourself

Delete template?

Save as template?